论文部分内容阅读
目的:观察阿魏酸钠联合缬沙坦治疗IgA肾病的临床疗效。方法:将60例IgA肾病患者随机分为治疗组(阿魏酸钠联合缬沙坦组)和对照组(缬沙坦组),治疗1个月后观察2组患者的血纤维蛋白原(FIB)、血清肌酐(Scr)、内生肌酐清除率(CCr)、24 h尿蛋白定量及内皮素(ET)水平。结果:与对照组相比,治疗组在降低FIB、Scr、ET水平,提高CCr水平等方面均优于对照组(P<0.05或P<0.01);治疗后2组24 h尿蛋白定量组间比较差异无统计学意义(P>0.05)。结论:阿魏酸钠联合缬沙坦可有效降低IgA肾病尿蛋白,改善Scr、CCr水平,改善内皮功能及血液高黏状态,对IgA肾病有良好的治疗价值。
Objective: To observe the clinical efficacy of sodium ferulate combined with valsartan in the treatment of IgA nephropathy. Methods: Sixty patients with IgA nephropathy were randomly divided into treatment group (sodium ferulate combined with valsartan group) and control group (valsartan group). After treatment for one month, fibrinogen (FIB ), Serum creatinine (Scr), endogenous creatinine clearance (CCr), 24 h urinary protein and endothelin (ET) levels. Results: Compared with the control group, the treatment group was better than the control group (P <0.05 or P <0.01) in reducing the levels of FIB, Scr and ET, and increasing the level of CCr. After treatment, The difference was not statistically significant (P> 0.05). Conclusion: Sodium ferulate combined with valsartan can effectively reduce urinary protein in patients with IgA nephropathy, improve Scr and CCr levels, improve endothelial function and blood viscosity state and have good therapeutic value on IgA nephropathy.